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Abstract
Background: Recent analyses of antiepileptic drugs have indicated an increase in the risk of suicidality. The
objective of this report was to provide clinical information and an independent meta-analysis of divalproex sodium
and suicidality events by analyzing data from 13 placebo-controlled studies and 1 low-dose controlled study.
Methods: Adverse events considered to be possibly suicide related were identified using the Columbia
Classification Algorithm of Suicide Assessment (C-CASA) methodology. Indications included epilepsy, bipolar
disorder, migraine prophylaxis, impulsive aggression, and dementia. Narratives were produced for every event, and
suicidality event ratings were performed by a third party blinded to treatment assignment. Statistical analyses were
conducted using methodology similar to that reported by the US Food and Drug Administration (FDA).
Results: Suicidality events were identified in 5 of the 13 placebo-controlled studies. Of the 1,327 (0.83%) subjects
taking divalproex sodium, 11 had suicidality events: 2 suicide attempts and 9 suicidal ideation. Of 992 (0.91%)
subjects taking placebo, 9 had suicidality events: 1 preparatory act toward suicide, 2 suicide attempts, and 6
suicidal ideation. Across placebo-controlled studies, the overall estimated odds ratio (OR) of suicidal behavior or
ideation was 0.72 (95% CI 0.29 to 1.84). The OR for suicidal behavior was 0.37 (95% CI 0.04 to 2.58), and the OR for
suicidal ideation was 0.90 (95% CI 0.31 to 2.79).
Conclusions: In this meta-analysis, divalproex sodium does not appear to increase the risk of suicide-related
adverse events relative to placebo in the populations studied. Clinicians should nonetheless remain vigilant in
assessing suicidality, not only in patients treated for mental disorders with inherently high suicide risk, but also in
patients taking antiepileptic medications.
Background
The latest World Health Organization statistics revealed
that approximately 800,000 people commit suicide
annually worldwide [1]. In the US, the suicide rate was
10.9 per 100,000 and was the second leading cause of
death in the 25-34-year-old age group in 2006 [2]. The
term suicidality encompasses a spectrum of events of
varied severity, ranging from suicidal ideation to suicidal
behavior and suicide. Approximately 6 years ago, the US
Food and Drug Administration (FDA) evaluated the
association between antidepressant agents and the
increased risk of suicidality. More recently, this investi-
gation was extended to the use of other medications
including antiepileptic drugs (AEDs). FDA analyses
employed a retrospective systematic search and
adjudication of spontaneously reported possibly suicide-
related adverse events from controlled clinical studies
[3]. In the case of antidepressants, the results of such
analyses led to the addition of a warning to prescribing
information regarding increased suicidality risk in the
pediatric population. The FDA published their statistical
review and evaluation of AEDs and suicidality in 2008
[4], which has also led to prescribing information modi-
fications [5].
Certain patient populations treated with AEDs, such
as those with epilepsy and bipolar disorder, are known
to be at increased risk of suicide. Evaluating the associa-
tion between AED therapy and suicidality in these popu-
lations may therefore be confounded by the high
incidence of suicidality associated not only with disease
states per se, but the risk associated with comorbid psy-
chiatric conditions. Epilepsy is a disorder associated
with considerable affective symptomatology in those
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any medium, provided the original work is properly cited.with this illness [6-9]. Patients with epilepsy have been
reported to be five times more likely to commit suicide
than the general population [10]. In addition, 25% of
epilepsy patients in the community are thought to
experience suicidal ideation compared to 13.3% of
patients without epilepsy [11]. A meta-analysis of suicide
risk indicated that patients with bipolar disorder are 16
times more likely to commit suicide than the general
population [10]. In the most recent Centers for Disease
Control Surveillance for Violent Deaths, 13.4% of people
who had committed suicide had a diagnosis of bipolar
disorder [2]. Among patients admitted to an emergency
room for suicide attempts, those attempting suicide
were five times more likely to have bipolar disorder
than those presenting to the emergency room for non-
suicide related psychiatric issues [12].
Divalproex sodium (DVPX) is an AED widely used in
epilepsy, the treatment of manic episodes associated
with bipolar disorder, and migraine prophylaxis [13].
From 2005 to 2007, the FDA acquired placebo-con-
trolled clinical study data from the manufacturers of 11
different AEDs. The purpose of the meta-analysis was to
determine whether the use of AEDs conferred a risk of
suicide-related adverse events, and the detailed methods
have been presented elsewhere [4]. The primary end-
point of the FDA analysis was suicidal behavior or idea-
tion. Patients with completed suicides, suicide attempts,
preparatory acts toward imminent suicidal behavior, or
suicidal ideation were considered to meet the primary
endpoint. Suicidal behavior (completed suicide, suicide
attempt, or preparatory acts toward imminent suicidal
behavior) and suicidal ideation were the two secondary
endpoints. Subgroup analyses were conducted in each
AED individually, as well as by drug group (sodium
channel blockers, g-aminobutyric acid (GABA)ergic and
GABAmimetics, carbonic anhydrase inhibitors), trial
indication (epilepsy, psychiatric, other), demographic
characteristics, setting (inpatient or inpatient/outpatient
combined, outpatient), and location (North America,
non-North America) [4].
DVPX was among the 11 AEDs assessed by the FDA
to determine the potential risk of suicidality from the
use of these drugs. A dataset was provided by the spon-
sor (Abbott, Abbott Park, IL, USA) to the FDA, contain-
ing data from 14 clinical trials conducted to evaluate the
efficacy and safety of DVPX in various indications. The
FDA suicidality meta-analysis of the 11 AEDs included a
total of 199 placebo-controlled clinical studies (43,892
subjects) and 11 low-dose-controlled studies (1,587 sub-
jects). In the FDA meta-analysis of placebo-controlled
trials, the overall estimated odds ratio (OR) for a suici-
dal behavior or ideation event was 1.80 (95% CI 1.24 to
2.66) for the combined 11 AEDs when compared to pla-
cebo. Individually, DVPX had an OR for a suicidal
behavior or ideation event of 0.72 (95% CI 0.29 to 1.84)
when compared to placebo. When analyzed by indica-
tion, the FDA reported that the OR for a suicidal beha-
vior or ideation event in patients with epilepsy was 3.53
(95% CI 1.28 to 12.10) and was 1.51 (95% CI 0.95 to
2.45) in the psychiatric population [4].
The DVPX prescribing information has been modified
to highlight the increased risk of suicidal thoughts and
behavior based on the FDA meta-analysis. Since the
FDA released their findings, clinicians using AEDs have
sought to put the information into a clinical context
[14-17]. The objective of this study was to assist clini-
cians by further contributing to the body of available
knowledge regarding suicidality and adverse events,
focusing specifically on DVPX. To accomplish this, the
same DVPX dataset provided to the FDA was analyzed
separately from the FDA meta-analysis. The data sum-
marized in this report are an individualized depiction of
suicidality and DVPX, and are distinct from the afore-
mentioned meta-analysis of 11 AEDs. The studies in the
following DVPX meta-analysis encompass a broad range
of indications including epilepsy, acute mania in bipolar
disorder, bipolar depression, dementia, migraine, and
i m p u l s i v ea g g r e s s i o n .I na d d i t i o nt oo v e r a l lr i s k ,t h e
risks of suicide-related events were calculated by study
and by indication. Details of each suicidality event from
the dataset are also presented for the first time.
Methods
The methods used for the selection of studies, search for
possibly suicide-related events and characterization of
identified events were based on instructions communi-
cated by the FDA directly to the sponsor. Analyses in
this report used the same dataset submitted to the FDA
for inclusion in their meta-analysis. A total of 13 pla-
cebo-controlled studies and 1 study using a subthera-
peutic dose of DVPX as a control were identified; all
were sponsored by Abbott (Table 1). Study durations
ranged from 3 to 52 weeks, with a mean duration of
approximately 13 weeks. Studies with less than 30 sub-
jects and ongoing blinded studies were excluded. The
study databases were searched for possibly suicide-
related adverse events (PSRAEs) that occurred during
the double-blind phase of treatment, within 1 day of
stopping randomized treatment, or on the first day of a
protocol-specified tapering period. Adverse events (AEs)
occurring prior to randomization or more than 1 day
after discontinuation from randomized treatment were
excluded. Only subjects taking DVPX or placebo were
analyzed; subjects from comparator arms were excluded.
Deaths, serious adverse events and accidental injury
events were identified. Preferred terms, verbatim terms,
and comment fields in the study databases were
searched to identify PSRAEs using the following text
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‘cut’, ‘gas’, ‘hang’, ‘hung’, ‘jump’, ‘mutilat-’, ‘self damag-’,
‘self harm’, ‘self inflict’, ‘self injur-’, ‘shoot’, ‘slash’, ‘poi-
son’, ‘asphyxiation’, ‘suffocation’, ‘firearm’, ‘burn’,
‘drown’, ‘gun’, ‘immolate’,a n d‘monoxide’. Additional
information was obtained from clinical research forms,
hospital records, consult results, and psychiatric rating
scales.
Narrative summaries were generated for subjects iden-
tified with a PSRAE using a systematic approach as out-
lined in the Columbia Classification Algorithm for
Suicide Assessment (C-CASA) [3]. Briefly, the C-CASA
is a rating system designed to independently and
reliably identify suicide-related adverse events from
blinded narratives describing PSRAEs. In this evaluation,
details in the narratives such as subject identifiers, spon-
sor name, investigator or site information, study drug,
and concomitant medications were concealed to reduce
potential bias during assessment. The blinded narratives
were forwarded to a third party subject matter expert at
Columbia University (New York, NY, USA) for severity
rating of the PSRAEs using C-CASA methodology and
definitions as described in Table 2 [3]. Codes 7 or 8
were later recoded to 0. Only PSRAEs coded 1 to 4
were considered suicidality events and included in the
FDA analysis.
Table 1 Study descriptions and number of subjects
Indication Study and year of
publication
Description Treatment
duration, weeks
Dose and/or target
trough drug level
Treatment group Total,
N = 2,319
DVPX, N =
1,327
Placebo, N
= 992
Placebo-controlled studies
Epilepsy Willmore et al. 1996
[30]
Adjunctive
therapy in CPS
16 90 mg/kg/day max 77 70 147
Total 77 (6%) 70 (7%) 147 (6%)
Psychiatric Pope et al. 1991 [31] Acute mania
a 3 50-100 μg/ml 20 23 43
Bowden et al. 1994
[32]
Acute mania
a 3 150 μg/ml 69 74 143
Bowden et al. 2000
[33]
Mania
maintenance
52 71-125 μg/ml 187 94 281
Sachs et al. 2001 [34] Bipolar
depression
16 250 mg/day initial with
titration
b
23 22 45
Hirschfeld et al. 2010
[35]
Acute mania
a 3 20 mg/kg/day with
increases allowed
146 78 224
Tariot et al. 2001 [36] Dementia
a 6 30 mg/kg/day max 87 85 172
Bowden et al. 2006
[37]
Acute mania
a 3 85-125 μg/ml 192 185 377
Hollander et al. 2003
[38]
Impulsive
aggression
12 80-120 μg/ml, 30 mg/kg/
day max
124 122 246
Placebo-controlled
study
c
Dementia
a 6 500 or 1,000 mg/day 78 43 121
Total 926 (70%) 726 (73%) 1652 (71%)
Migraine Mathew et al. 1995
[39]
Migraine
prophylaxis
12 70-120 μg/ml 70 37 107
Klapper 1997 [40] Migraine
prophylaxis
12 500, 1,000 or 1,500 mg/day 132 44 176
Freitag et al. 2002 [41] Migraine
prophylaxis
12 500 or 1,000 mg/day 122 115 237
Total 324 (24%) 196 (20%) 520 (22%)
High-dose DVPX vs low-dose DVPX
Trough levels High-dose
DVPX
Low-dose
DVPX
Epilepsy Beydoun et al. 1997
[42]
Monotherapy in
CPS
24 25-50 μg/ml and 80-150
μg/ml
131 134 265
aInpatient study; all others were conducted in an outpatient setting;
binitiated at 250 mg, titrated by 250 mg/day on alternate days until reaching one of three
criteria: serum trough concentration ≥45 μg/ml and HAM-D improvement ≥60% from baseline, ≥75 μg/ml and HAM-D ≥50% from baseline, or ≥95 μg/ml and
HAM-D ≥30% from baseline; cData obtained from Abbott Protocol M99-082 clinical study report (unpublished). CPS = complex partial seizures; DVPX = divalproex
sodium; HAM-D = Hamilton Rating Scale for Depression.
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The meta-analysis methodology employed by the FDA
in the evaluation of suicidality risk across 11 AEDs was
utilized as the primary method to assess the risk of sui-
cidality across multiple DVPX studies [4]. Delayed-
release and extended-release DVPX formulations were
combined and analyzed as DVPX treatment. To be con-
sistent with the conservative approach employed by the
FDA, the most severe suicidality event was included in
the evaluation in situations where subjects experienced
more than one event. The overall ORs of suicidality
events across studies and associated 95% CIs were calcu-
lated using the exact method controlling for study [18].
For studies with no suicidality events, OR could not be
calculated due to zeros in both the numerator and
denominator. Therefore these studies could not be
included in any of the overall OR analyses controlling
for study. Zelen’s test, an exact test for homogeneity of
OR among studies, was conducted [18]. As a sensitivity
analysis, SAS procedure GLIMMIX [19] (SAS, Cary, NC,
USA) was used to estimate the OR using a generalized
linear mixed model where study was considered as a
random factor. The Mantel-Haenszel risk difference
controlling for study and associated CI [20] were gener-
ated which included the zero-event studies. Relative risk
analysis employing the exact method was also conducted
[18]. This analysis used subject time as the unit of ana-
lysis rather than using the subject as the unit in the esti-
mation of the OR. The overall absolute risks and relative
risks from the pooled dataset were calculated for all pla-
cebo-controlled studies combined, for all placebo-con-
trolled and low-dose-controlled studies combined, and
by indication. These calculations did not use study as a
stratification factor.
Results
Demographics, baseline characteristics, and duration
There were 13 placebo-controlled studies and 1 study
comparing a high-dose with a low-dose of DVPX.
Descriptions of the studies and corresponding numbers
of subjects included in the analyses are presented in
Table 2. All studies were conducted in the US and were
completed prior to 2005.
Of 2,319 subjects from placebo-controlled studies (n =
1,327 for DVPX and n = 992 for placebo), 6% partici-
pated in an epilepsy study, 71% in psychiatry studies,
and 22% in migraine studies. Subject demographic char-
acteristics from these 13 studies are presented in
Table 3. The mean age in both treatment groups was 44
years (range 9 to 100), and the majority of the subjects
(83%) were Caucasian. The mean participation duration
was 68 days in DVPX-treated subjects (range 1 to 400)
Table 2 Suicidality event rating definitions
Code no. Category C-CASA definition
a
1 Completed suicide A self-injurious behavior that resulted in fatality and was associated with at least some intent
to die as a result of the act
2 Suicide attempt A potentially self-injurious behavior, associated with at least some intent to die, as a result of
the act. Evidence that the individual intended to kill him/herself, at least to some degree, can
be explicit or inferred from the behavior or circumstance. A suicide attempt may or may not
result in actual injury.
3 Preparatory acts toward imminent
suicidal behavior
The individual takes steps to injure him or herself, but is stopped by self or others from
starting the self-injurious act before the potential for harm has begun
4 Suicidal ideation: passive, active, active
with plans, type unknown
Passive thoughts about wanting to be dead or active thoughts about killing oneself, not
accompanied by preparatory behavior
5 Self-injurious behavior, intent unknown Self-injurious behavior where associated intent to die is unknown and cannot be inferred. The
injury or potential for injury is clear, but why the individual engaged in that behavior is
unclear.
6 Not enough information: death Insufficient information to determine whether the event involved deliberate suicidal behavior
or ideation. There is reason to suspect the possibility of suicidality but not enough to be
confident that the event was not something other, such as an accident or psychiatric
symptom.
7 Self-injurious behavior, no suicidal intent Self-injurious behavior associated with no intent to die. The behavior is intended purely for
other reasons, either to relieve distress (often referred to as ‘self-mutilation’, for example
superficial cuts or scratches, hitting/banging, or burns) or to effect change in others or the
environment.
8 Other: accident, death, psychiatric,
medical
No evidence of any suicidality or deliberate self-injurious behavior associated with the event.
The event is characterized as an accidental injury, psychiatric or behavioral symptoms only, or
medical symptoms or procedure only.
9 Not enough information: non-death Same as no. 6 above, with the event not resulting in death
aDefinitions from [3]: Posner et al., Am J Psych 2007, 164:1035-1043.
C-CASA = Columbia Classification Algorithm for Suicide Assessment.
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There were no statistically significant differences
between the two treatment groups in terms of age, gen-
der, race, or duration of study participation.
Suicidality events
When counting the single most severe suicidality event
(codes 1-4) for subjects experiencing any event, 20 sub-
jects from 5 of the 13 placebo-controlled studies experi-
enced a suicidality event: 0 completed suicides,
4 suicide attempts (2 DVPX, 2 placebo), 1 preparatory
act toward suicide (placebo), and 15 suicidal ideation
(9 DVPX, 6 placebo). One low-dose DVPX subject in
the epilepsy, adjunctive complex partial seizures (CPS)
trial experienced suicidal ideation. No suicidality events
occurred in the migraine prophylaxis or dementia stu-
dies. All but one of the subjects with suicidality events
experienced the event in an outpatient setting, and 90%
of the subjects who had suicidality events were white.
Additional details regarding suicide-related events by
severity and indication are presented in Table 4. The
largest number of subjects experienced suicidality events
during the 52-week mania maintenance study, seven
(3.7%) in the DVPX group and seven (7.5%) in the pla-
cebo group. Three of the four suicide attempts occurred
in this long-term bipolar maintenance study (two
DVPX, one placebo), with the other occurring during a
bipolar depression study (placebo). Three of the four
subjects with suicide attempts had a known history of
previous suicide attempts, and two of them had
attempted suicide in the 12 months preceding study
entry.
Two subjects reported more than one suicidality event
during a study. One subject taking DVPX experienced
suicidal ideation on days 44 and 234 of the bipolar
maintenance study. Another subject taking placebo in
the bipolar depression study experienced suicidal idea-
tion on day 17, and attempted suicide on day 19. This
subject had previously attempted suicide within the
12 months prior to entering the study.
Meta-analysis results
The incidence of suicidality events, ORs by study, and
estimated overall OR across five placebo-controlled stu-
dies with at least one event are presented in Table 5.
None of the ORs comparing DVPX with placebo were
statistically significantly different from 1. A total of 11
(0.83%) subjects exposed to DVPX experienced suicidal
behavior or ideation while 9 (0.91%) placebo-treated
subjects reported suicidality events. The overall esti-
mated OR of suicidal behavior or ideation was 0.72
(95% CI 0.29 to 1.84). For the placebo-controlled stu-
dies, the OR for suicidal behavior was 0.37 (95% CI 0.04
to 2.58), and the OR for suicidal ideation was 0.90 (95%
CI 0.31 to 2.79).
Zelen’s test for the null hypothesis that all studies had
a common OR for suicidality events had a P value of
0.467, indicating a homogenous OR of suicidality events
across studies. The OR estimated from a generalized lin-
ear mixed model with fixed effect for treatment and a
Table 3 Demographic characteristics: placebo-controlled studies
Characteristic Treatment group Total, N = 2,319, n (%) P value
DVPX, N = 1,327, n (%) Placebo, N = 992, n (%)
Age, years Mean ± SD 44 ± 18 44 ± 19
Least-squares mean 45 46 0.7454
a
Range 10 to 100 9 to 99
5 to 17 15 (1) 12 (1) 27 (1) 0.1413
b
18 to 24 131 (10) 83 (8) 214 (9)
25 to 30 140 (11) 138 (14) 278 (12)
31 to 64 855 (64) 617 (62) 1,472 (63)
≥65 186 (14) 142 (14) 328 (14)
Gender Female 740 (56) 544 (55) 1,284 (55) 0.3087
b
Male 587 (44) 448 (45) 1,035 (45)
Race White Caucasian 1,109 (84) 825 (83) 1,934 (83) 0.4430
b
Other 218 (16) 167 (17) 385 (17)
Participation duration, days Mean ± SD 68 ± 84 57 ± 64 0.2344
a
Least-squares mean 60 57
Range 1 to 400 1 to 391
aP value for the treatment group difference is from a two-way analysis of variance with the terms of treatment and study.
bP value for the treatment group difference is from the Cochran-Mantel-Haenszel general association test controlling for study.
DVPX = divalproex.
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Study Treatment Event,
study
day(s)
Age,
years
Gender Adverse event term(s) Relevant history
Completed suicide: 0
Suicide attempts: 4
Mania
maintenance
DVPX 241 21 Female Overdose, suicide
attempt
Benzodiazepine overdose after a family conflict. Family history of
bipolar disorder; history of previous SA.
Mania
maintenance
DVPX 313 43 Female Manic depressive
reaction, overdose,
suicide attempt
Benzodiazepine overdose. Family history of alcoholism, ADHD;
previous SA approximately 12 months prior; SADS-C suicidal
tendency score was 1 (not at all) on day 308.
Mania
maintenance
Placebo 71 29 Female Overdose Benzodiazepine + alcohol combination ‘due to poor judgment’.
Marital break-up and lost custody of children. Family history of
anxiety, depression.
Bipolar
depression
a
Placebo 19 18 Male Euphoria, abdominal
pain, overdose
Amphetamine overdose. One SA in past year; mother died in past
year; HAM-D rated as 0 (absent) and BPRS rated as 0 (not present)
on day 15.
Preparatory acts toward imminent suicidal behavior: 1
Mania
maintenance
Placebo 29 26 Female Depression Severe depression and suicidal ideation 1 day post treatment.
Family history of mood, eating, and drug abuse disorders; history
of borderline personality disorder; five SA since 1983 (last
approximately 1 year prior); SADS-C rated as 1 (not at all) on day
-1, 2 (slight) on day 7 and 5 (severe) on day 29.
Suicidal ideation: 15
b
Epilepsy,
adjunctive
CPS
DVPX 19 21 Female Depression Severe thoughts of suicide that resolved the next day. History of
drug abuse (approximately 1 year recovered), violent during
seizures, and decreased mental sharpness; CBZ.
Acute mania DVPX 2 33 Female Depression Moderate suicidal thoughts lasting 6 hours after a ‘family event’.
SADS-C rated as 0 (not at all) on day -1 and day 5.
Mania
maintenance
DVPX 24 52 Male Depression Moderate suicidal ideation. Family history of suicide, abuse,
electroconvulsive therapy, and residing in mental institution;
history of obesity, diabetes, cardiovascular disease; SADS-C rated as
2 (slight) on day 15 and 4 (moderate) on day 30.
Mania
maintenance
DVPX 23 31 Female Depression Severe depression, BDI indicated suicidal ideation. Family history of
mood swings; SADS-C rated as 1 (not at all) on days -1 and 7, and
5 (severe) on day 24.
Mania
maintenance
DVPX 196 22 Male Depression Severe depression and suicidal ideation. SADS-C rated as 3 (mild)
on day 1.
Mania
maintenance
DVPX 1 28 Male Thinking abnormal
thoughts
Moderate fleeting thoughts of wanting to hurt self (non-suicidal).
SADS-C rated as 1 (not at all) on day -1, and 2 (slight) on day 18.
Mania
maintenance
DVPX 44, 234 45 Male Depression Two episodes of suicidal ideation (severe and mild, respectively).
Family history of depression; SADS-C rated as 6 (extreme) on day
55 and 3 on day 218; paroxetine.
Impulsive
aggression
DVPX 16 37 Male Depression Severe hostility, depression and suicidal ideation, ‘stress due to
friend’s death’. History of major depression, HIV positive (3
months), childhood physical abuse, possible PTSD; HAM-D rated as
1 (life not worth living) on day -22.
Impulsive
aggression
DVPX 38 36 Female Depression Moderate feelings of worthlessness and hopelessness, mild
thoughts of suicide. History of intermittent explosive disorder,
alcohol dependence, cluster B personality disorder-borderline;
HAM-D was rated as 0 (absent) on days 28 and 48.
Mania
maintenance
Placebo 54 31 Male Depression Severe suicidal ideation and intent. Family history of depression;
history of panic attacks; SADS-C rated as 3 (mild) on day 43 and 6
(extreme) on day 54; thyrosin, sertraline.
Mania
maintenance
Placebo 188 45 Female Manic depressive
reaction
Severe suicidal ideation. Family history of bipolar disorder,
depression; SADS-C rated as 1 (not at all) on day 175 and 5
(severe) on day 188.
Mania
maintenance
Placebo 116 41 Female Manic depressive
reaction
Severe suicidal ideation and psychosis; SADS-C rated as 1 (not at
all) on day 111 and 4 (moderate) on day 116.
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The overall risk difference between DVPX treatment
and the placebo group was -2.75 (95% CI -10.68 to 5.17)
per 1,000 subjects and was not significantly different
from zero. The relative risk comparing DVPX with pla-
cebo, adjusting for subject exposure, was 0.64 (95% CI
0.26 to 1.62) and not statistically significantly different
from 1. The statistical inferences from these sensitivity
analyses are consistent with those obtained from the pri-
mary analysis.
The single low-dose-controlled study was not included
in the previous analyses because the design did not
include a placebo control. In this monotherapy study in
subjects with complex partial seizures, one subject in
the low-dose DVPX treatment group experienced suici-
dal ideation. When analyzed individually, the OR of
Table 5 Odds ratios by study and overall odds ratio estimated for low-dose and placebo-controlled studies
Study Population Treatment group OR (95% CI)
DVPX, N = 1,327, n/N
a Placebo, N = 992, n/N
a
Placebo-controlled studies
Willmore et al. 1996 [30] Epilepsy 1/77 0/70 2.76 (0.11 to 68.98)
Pope et al. 1991 [31] Acute mania 0/20 0/23 -
Bowden et al. 1994 [32] Acute mania 0/69 0/74 -
Bowden et al. 2000 [33] Mania maintenance 7/187 7/94 0.48 (0.16 to 1.42)
Sachs et al. 2001 [34] Bipolar depression 0/23 1/22 0.31 (0.01 to 7.89)
Hirschfeld et al. 2010 [35] Acute mania 1/146 0/78 1.62 (0.07 to 40.20)
Tariot et al. 2001 [36] Dementia 0/87 0/85 -
Bowden et al. 2006 [37] Acute mania 0/192 0/185 -
Hollander et al. 2003 [38] Impulsive aggression 2/124 1/122 1.98 (0.18 to 22.16)
Placebo-controlled study
b Dementia 0/78 0/43 -
Mathew et al. 1995 [39] Migraine 0/70 0/37 -
Klapper 1997 [40] Migraine 0/132 0/44 -
Freitag et al. 2002 [41] Migraine 0/122 0/115 -
Overall (placebo-controlled) 11/557
c 9/386
c 0.72 (0.29 to 1.84)
High-dose DVPX vs low-dose DVPX
High-dose DVPX Low-dose DVPX
Beydoun et al. 1997 [42] Epilepsy 0/131 1/134 0.34 (0.01 to 8.38)
Overall (all studies) 11/688
c 10/520
c 0.66 (0.27 to 1.64)
aN = the number of subjects treated in the study for the prospective treatment group.
bData obtained from Abbott Protocol M99-082 clinical study report (unpublished).
cThe denominator presents the total number of subjects in the studies with at least one suicidality event and therefore included in the overall OR calculation.
DVPX = divalproex sodium; NA = not applicable; OR = odds ratio; - = zero-event studies, OR cannot be estimated.
Table 4 Characteristics of suicidality events (Continued)
Mania
maintenance
Placebo 131 38 Male Depression Mild and transient suicidal ideation after ethanol consumption.
Family history of bipolar disorder; SADS-C rated as 2 (slight) on day
115.
Mania
maintenance
Placebo 39 32 Female Psychotic depression Severe depression and suicidal ideation. Family history of
depression; SADS-C rated as 3 (mild) on day 28.
Impulsive
aggression
Placebo 20 31 Female Depression Mild suicidal ideation with no plans/means that resolved within 2
hours. History of major depression, physical abuse, witnessed
domestic violence, borderline cluster B personality disorder; HAM-D
rated as 0 (absent) on day -15 and 28.
Epilepsy,
monotherapy
Low-dose
DVPX
17 33 Female Depression Moderate depression and thoughts of suicide. Marital and financial
issues; history of anxiety, CBZ.
aThis subject also experienced an event of suicidal ideation (code 4) on day 17; only the most severe event is included in this table.
bN = 15 in placebo-controlled studies when counting the most severe event in patients experiencing >1 event.
ADHD = attention-deficit hyperactivity disorder; BDI = Beck Depression Inventory; BPRS = Brief Psychiatric Rating Scale suicidal thoughts; CBZ = carbamazepine;
CPS = complex partial seizures; DVPX = divalproex sodium; HAM-D = Hamilton Depression Rating Scale suicide score; PTSD = post-traumatic-stress disorder; SA =
suicide attempt; SADS-C = Schedule for Affective Disorders and Schizophrenia-Change Version suicidal tendency score.
Redden et al. Annals of General Psychiatry 2011, 10:1
http://www.annals-general-psychiatry.com/content/10/1/1
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high-dose group and the low-dose group was 0.34 (95%
CI 0.01 to 8.38). Combining the low-dose study with the
placebo-controlled studies and pooling the low-dose
group with the placebo group yielded an OR of 0.66
(95% CI 0.27 to 1.64) for suicidality events (Table 5).
Table 6 presents the overall absolute risk, relative risk,
and risk difference for all placebo-controlled and low-
dose-controlled studies (total and by indication), as well
as for all placebo-controlled studies combined by pool-
ing the subjects from respective studies together. The
relative risk was numerically higher in the epilepsy
group (0.98) than in the psychiatric group (0.87).
Discussion
Higher rates of suicidality have been previously reported
for populations that take AEDs for different indications,
particularly subjects with epilepsy [10] and bipolar disor-
der [2,10]. Determining whether AED use increases sui-
cidality in patients taking these medications is a
complex task, and research in this area continues. One
recent example is a large pharmacoepidemiological
study of patients taking AEDs or lithium as monother-
apy for bipolar disorder conducted by Gibbons et al.
[14]. Medical claims data from 47,918 patients with
bipolar disorder were studied. Patient data was included
if it encompassed at least 1 year pre-illness and post-
illness index date. The authors reported that suicide
attempt rates were significantly greater before AED
therapy was initiated (72 per 1,000 person-years) com-
pared to 13 per 1,000 person-years after treatment
began (P < 0.001). For patients not treated with any cen-
tral nervous system drug, suicide attempts were 15 per
1,000 person-years, compared with 3 per 1,000 person-
years in patients treated with an AED (P < 0.001) [14].
In the present analysis, treatment with DVPX in a
variety of conditions did not appear to increase the risk
of suicide-related AEs relative to that of placebo, consis-
tent with the DVPX OR of 0.72 (95% CI 0.29 to 1.84)
estimated by the FDA during individual AED analyses.
When examining all 14 DVPX studies combined, the
relative risk was <1 for both the epilepsy and psychiatric
populations, but slightly higher in epilepsy subjects com-
pared to psychiatric study subjects. These estimates cor-
respond to the FDA results indicating that the relative
risk for suicidal thoughts or behavior was higher in clin-
ical trials for epilepsy than in clinical trials for psychia-
tric or other conditions.
Although systematic retrospective reviews of clinical
study data yield useful information, this approach has
some limitations. The observation that treatment with
DVPX did not increase the risk of suicidality events dif-
fers from the overall conclusions of FDA meta-analysis
of 11 AEDs. This inconsistency may be related to the
size of the datasets analyzed. The DVPX data are
obviously a subset of the much larger dataset collected
by the FDA, and this smaller population may have pre-
vented the detection of uncommon events. Additionally,
the AEDs analyzed belong to multiple pharmacological
classes. This may be an important factor to consider
when interpreting pooled data in the determination of
suicidality risk associated with the use of these drugs
because the different mechanisms of action could be a
confounding factor. None of the DVPX clinical studies
were specifically designed to assess suicidality ap r i o r i ,
and the study designs, DVPX doses, and types of data
collected from a variety of populations was highly vari-
able. The retrospective nature of the analysis may have
led to ascertainment bias, making it difficult to draw
definitive conclusions regarding the causality of events.
In addition, data from controlled trials may not translate
to larger populations. Not only were subjects selected
based on specific study criteria, but it is also possible
that protocol-specified interventions may have alleviated
Table 6 Absolute and relative risk by indication and overall (pooled datasets)
Placebo DVPX Relative risk Risk difference per
1,000 subjects
n/N Absolute risk per
1,000 subjects
n/N Absolute risk per
1,000 subjects
Incidence of events in DVPX subjects/
incidence in placebo subjects
Additional DVPX
subjects with events
Placebo-controlled and low-dose-controlled studies
Indication:
Epilepsy 1/204 4.90 1/208 4.81 0.98 -0.09
Psychiatric 9/726 12.40 10/926 10.80 0.87 -1.60
Migraine 0/196 0.00 0/324 0.00 - 0.00
Total 10/1,126 8.88 11/1,458 7.54 0.85 -1.34
Placebo-controlled studies
Total 9/992 9.07 11/1,137 8.29 0.91 -0.78
DVPX = divalproex sodium; n = number of subjects with events across studies; N = number of subjects treated across studies; - = relative risk cannot be
calculated due to zero events in studies.
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Page 8 of 10participants’ psychiatric symptoms. The larger number
of events reported in the 52-week bipolar maintenance
study may have been associated with the longer duration
of follow-up or the illness per se. As 83% of study parti-
cipants in the pooled dataset were Caucasian, racial or
regional differences in suicide-related adverse events
may not be reflected in this dataset.
It is important to note that when interpreting research
regarding suicidality it is not possible to predict whether
an event of lesser severity such as suicidal ideation will
ultimately lead to suicide [21-23]. It is clear that evidence
of suicidality must be clinically assessed to prevent pro-
gression to more serious events. A recent analysis of the
National Comorbidity Survey Replication indicated that
in a population of community dwelling US adults,
approximately 80% of those who attempt suicide had a
psychiatric disturbance prior to the suicide attempt [23].
Major depression, affective disorders, psychoses, sub-
stance abuse, and personality disorders have been
reported to place patients with epilepsy at higher risk of
suicide. In a prospective analysis of a large group of bipo-
lar patients followed for 2 years, history of suicide
attempt (OR = 4.52, P < 0.0001) and the percentage of
days depressed during the previous year (OR = 1.16, P =
0.036) were significantly related to suicide attempts and
completions [24]. Increasing awareness of suicidality,
assessing prior suicide-related events, and utilizing
appropriate psychiatric screening measures may therefore
serve to minimize risks of suicidality [15,24-29]. The
employment of prospective monitoring to assess suicidal
ideation and behaviors over time should overcome the
limited nature of retrospective evaluations while enhan-
cing patient safety and investigative outcomes.
Conclusions
In this meta-analysis, divalproex sodium does not appear
to increase the risk of suicide-related adverse events rela-
tive to placebo. Screening assessments combined with vigi-
lance on the part of clinicians remain important strategies
for reducing suicidality in patients treated with AEDs.
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